An Unusual Case of Combined Thrombosis and Amegakaryocytopenia Resembling Thrombosis With Thrombocytopenia Syndrome Following COVID-19 Infection in an Unvaccinated Patient

Article Medicine, General & Internal

Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021

Isaac See et al.

Summary: This study describes the surveillance data and reporting rates of TTS cases after COVID-19 vaccination in the United States. TTS cases were more common and had higher reporting rates after Ad26.COV2.S vaccination, with most cases requiring hospitalization. There were only a few reported cases and a lower reporting rate of TTS after mRNA-based COVID-19 vaccines.

ANNALS OF INTERNAL MEDICINE (2022)

Add to Collection

Article Immunology

Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination

Alessandra Buoninfante et al.

Summary: This article summarizes the discussion of an EMA workshop on the epidemiology, clinical presentation, and biology of thrombosis with thrombocytopenia syndrome after adenovirus vector COVID-19 vaccination. International regulators, scientists, and developers have reached a general agreement on the steps needed to improve the understanding of this new syndrome, including enhancing post-vaccination surveillance activities in low and middle income countries and investigating potential genetic predisposition factors.

NPJ VACCINES (2022)

Add to Collection

Review Pathology

Postmortem Findings Associated With SARS-CoV-2 Systematic Review and Meta-analysis

Swati Satturwar et al.

Summary: Autopsy findings from COVID-19 and SARS-CoV-1 cases suggest that DAD is more common in SARS-CoV-1, while hepatic necrosis, splenic necrosis, and white pulp depletion are more frequently associated with SARS-CoV-1 compared to COVID-19 cases.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2021)

Add to Collection

Article Hematology

Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)

Johannes Thaler et al.

Summary: In cases of VIPIT following ChAdOx1 nCoV-19 vaccination, early initiation of treatment can effectively reduce the risk of thrombosis and lead to rapid improvement in the patient's health without thrombotic complications.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Medicine, General & Internal

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Marie Scully et al.

Summary: 23 cases of thrombotic thrombocytopenia were reported after receiving the AstraZeneca vaccine, incited by antibodies to platelet factor 4 and unrelated to heparin therapy. Avoidance of platelet transfusion and consideration of nonheparin anticoagulant and intravenous immune globulin are recommended for treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Nina H. Schultz et al.

Summary: This study reports five cases of venous thrombosis and thrombocytopenia occurring 7 to 10 days after receiving the ChAdOx1 nCoV-19 vaccine, suggesting a rare vaccine-induced immune thrombotic thrombocytopenia. The condition, which can lead to catastrophic outcomes such as cerebral venous sinus thrombosis, may be treated with intravenous immune globulin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Editorial Material Medicine, General & Internal